A5058532121- Immune cells in cancer
- Chemokine receptors and signaling
- Acute Myeloid Leukemia Research
- Inflammation biomarkers and pathways
- Immune Cell Function and Interaction
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Cancer, Hypoxia, and Metabolism
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Antibiotics Pharmacokinetics and Efficacy
- Immunotherapy and Immune Responses
- Nosocomial Infections in ICU
- Cancer Research and Treatments
- CAR-T cell therapy research
- Antibiotic Resistance in Bacteria
- Angiogenesis and VEGF in Cancer
The Ohio State University
2023-2025
Comprehensive Blood & Cancer Center
2024
Xi'an Chest Hospital
2024
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2023-2024
Abstract Introduction As one of the major components tumor microenvironment, tumor-associated macrophages (TAMs) possess profound inhibitory activity against T cells and facilitate escape from immune checkpoint blockade therapy. Converting this pro-tumorigenic toward anti-tumorigenic phenotype thus is an important strategy for enhancing adaptive immunity cancer. However, a plethora mechanisms have been described differentiation in cancer, metabolic switches to program property TAMs are...
Wilms' tumour 1-associating protein (WTAP) is ubiquitously expressed in many tissues and plays an important role physiological processes development. Here, we investigated the specific biological underlying mechanism of WTAP melanoma. We determined expression its correlation with clinicopathological features paraffin-embedded tissues. effects on melanoma cells via a CCK-8 assay, colony formation EdU transwell assay subcutaneous xenograft experiments. then applied RNA sequencing to further...
Abstract Myeloid-derived suppressor cell (MDSC) levels are elevated in patients with cancer and contribute to reduced efficacy of immune checkpoint therapy. MDSC express Bruton's tyrosine kinase (BTK) BTK inhibition ibrutinib, an FDA-approved irreversible inhibitor BTK, leads expansion/function mice significantly improves the antitumor activity anti-PD-1 antibody treatments. Single-cell RNA sequencing (scRNA-seq) was used characterize effect ibrutinib on gene expression...
<p>Comparison of melanoma MDSC to breast (A-B) and head neck (C-D).</p>
<p>Individual UMAP plots melanoma MDSC treated with DMSO control or 5 µM ibrutinib for 4h.</p>
<div>Abstract<p>Myeloid-derived suppressor cell (MDSC) levels are elevated in patients with cancer and contribute to reduced efficacy of immune checkpoint therapy. MDSC express Bruton's tyrosine kinase (BTK) BTK inhibition ibrutinib, an FDA-approved irreversible inhibitor BTK, leads expansion/function mice significantly improves the antitumor activity anti-PD-1 antibody treatments. Single-cell RNA sequencing (scRNA-seq) was used characterize effect ibrutinib on gene expression...
<p>FACS purified MDSC viability after 24h DMSO or ibrutinib treatment.</p>
<p>Expression thresholds for CD14 gene expression.</p>
<p>MDSC isolation via FACS.</p>
<p>Pathway analysis results from IPA of melanoma MDSC treated with DMSO control or 4h ibrutinib.</p>
<p>Analysis of subsets (PMN-MDSC DE vs. double positive MDSC).</p>
<p>Pathway analysis results from IPA of melanoma MDSC treated with DMSO control or 4h ibrutinib.</p>
<p>MDSC isolation via FACS.</p>
<p>Expression thresholds for CD14 gene expression.</p>
<p>Analysis of subsets (PMN-MDSC DE vs. double positive MDSC).</p>
<p>FACS purified MDSC viability after 24h DMSO or ibrutinib treatment.</p>